uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 11/02/21
uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 10/25/21
uniQure Announces the Appointment of Rachelle Jacques to its Board of DirectorsGlobeNewsWire • 10/21/21
Will uniQure (QURE) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/19/21
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)GlobeNewsWire • 10/19/21
uniQure to Participate in Multiple Upcoming Industry Conferences in SeptemberGlobeNewsWire • 09/07/21
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 08/30/21
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 07/26/21
UniQure (QURE) to Report Q2 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 07/22/21
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual CongressGlobeNewsWire • 07/02/21
One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX LevelsBenzinga • 06/22/21
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve AcquisitionBenzinga • 06/22/21
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)GlobeNewsWire • 06/22/21
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory UpdateGlobeNewsWire • 06/22/21
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 06/16/21